Data from EMC - Curated by Toby Galbraith - Last updated 19 October 2016

Indication(s)

Thrombolytic treatment in acute myocardial infarction
- 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h after symptom onset
- 3 h dose regimen: for patients in whom treatment can be started between 6 - 12 h after symptom onset provided that the diagnosis has been clearly confirmed.

Actilyse has proven to reduce 30-day-mortality in patients with acute myocardial infarction.


Thrombolytic treatment in acute massive pulmonary embolism with haemodynamic instability
The diagnosis should be confirmed whenever possible by objective means such as pulmonary angiography or non-invasive procedures such as lung scanning. There is no evidence for positive effects on mortality and late morbidity related to pulmonary embolism.


Fibrinolytic treatment of acute ischaemic stroke
Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.

 

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Boehringer Ingelheim Limited

Related Content